According to a new market research report published by Global Market
Estimates, the Global Pulmonary Arterial Hypertension Market is projected
to grow at a CAGR of 11.5% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 151 Market Data Tables and 112 Figures spread through 189 Pages and in-depth TOC on “Global Pulmonary Arterial Hypertension Market- Forecast to 2027’’ https://www.globalmarketestimates.com/market-report/pulmonary-arterial-hypertension-market-3787
United Therapeutics Corporation, Bayer, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc. (Novartis), Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Teva Pharmaceutical Industries Ltd, among others, are the key players in the pulmonary arterial hypertension market.
Drug Class Outlook (Revenue, USD Billion, 2022-2027)
· Endothelin Receptor Antagonists (ERAs)
· PDE - 5 Inhibitors
· Prostacyclin and Prostacyclin Analogs
· SGC Stimulators
Type Outlook (Revenue, USD Billion, 2022-2027)
Route of Administration Outlook (Revenue, USD Billion, 2022-2027)
· Intravenous/ subcutaneous
Regional Outlook (Revenue, USD Billion, 2022-2027)
Central & South America
Middle East & Africa
Contact: Yash Jain
Email address: firstname.lastname@example.org
Phone Number: +1 6026667238